We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Richard Sterling MD, MSc, FACP, FACG, AGAF, FAASLD

Richard K. Sterling MD, MSc, FACP, FACG, AGAF, FAASLD

VCU Hepatology Professor of Medicine; Section Chief, Hepatology; Medical Director, Viral Hepatitis and HIV-Liver Disease; Program Director, Transplant Hepatology; Department of Internal Medicine, Divisions of Gastroenterology, Hepatology and Nutrition and Infectious Diseases, Virginia Commonwealth University Health System, Richmond, Virginia

Dr. Sterling received his BS in Chemistry and Natural Science from Muhlenberg College in Allentown Pa in 1982, a MA in Biochemistry from the University of Texas in Austin in 1984, and a MD from Jefferson Medical College in Philadelphia in 1988. He returned to VCU in 1997 and is currently a VCU Hepatology Professor of Medicine (promoted to tenure June 2011) in the Divisions of Gastroenterology, Hepatology, and Nutrition and Infectious Diseases. He is currently Section Chief of Hepatology, Medical Director of Viral Hepatitis at VCUHS, Associate Program Director for Scholarship and Research for the core Internal Medicine Residency, and Assistant Chair for Research in the Department of Medicine. His research interest is in HIV-liver disease which is supported by several U01 and R01 NIH grants. Other research interests include noninvasive assessment of liver disease, biomarkers for hepatocellular carcinoma, viral hepatitis, and liver transplantation. He has published over 230 manuscripts, several book chapters and serves on several prominent committees of national associations such as the ABIM, AGA, AASLD, and ACG and has served on several study sections of the NIH. He has won numerous awards for teaching and leadership and was voted “Top Doc” in 2012, 2013 and 2022 in Richmond magazine.

Disclosures

Research to VCU: Merck, Gilead, Abbvie, Roche, Abbott

Advisory Board: Pfizer, Baxter, Gilead, Abbvie, Salix

Speaker: none

Recent Contributions to PracticeUpdate:

  1. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Detecting Liver Fibrosis in Low-Prevalence Populations
  2. Effectiveness of the Structured Early Detection of Asymptomatic Liver Cirrhosis Program
  3. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in HCV–Related HCC
  4. Outcomes Following Liver Transplant of HCV-Viremic Donors
  5. Cost-Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy

Most Read This Week

Recently Updated